Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen: Nov 20, 2008

Premium
Invitrogen has introduced the Invivofectamine delivery reagent for the delivery of siRNAs in vivo.
 
According to the company, the reagent can be injected in small volumes and without high pressure, and provides extra stability to siRNA so the oligo will arrive at its target intact. The reagent is non-viral and has minimal toxicity, the company added.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more